TrialLipids2014

Treatment of low HDL-C subjects with the CETP modulator dalcetrapib increases plasma campesterol only in those without ABCA1 and/or ApoA1 mutations.

Eric J Niesor et al.PubMed ↗Publisher ↗

No numbers read from the abstract.